The First Annual ACT Meeting brought together various Canadian biotechnology companies interested in working with the ACT partnered Networks.
‘As the next ACT Request for Applications (RFA) involves biotechnology partnerships (Spring 2023), please refer to the list of biotechnology companies and their contact information:
If you have any questions, please contact Kevin O’Neil at [email protected].
The ACT Canada Consortium consists of hundreds of investigators, stakeholders, and highly qualified research personnel from 11 trial units and 28 research networks across Canada. The central guiding principle of the ACT Consortium is that its activities will accelerate, optimize, and facilitate the conduct, implementation, and results translation from high-quality, high-impact randomized controlled trials (RCTs) to improve health in Canada and around the world.
CANet is one of the many networks that is supported by ACT which allows CANet Network Investigators to apply for research monies and in-kind support for clinical trials.
ACT is providing research personnel to our Network to improve our infrastructure support and further our Network activities. Examples of in-kind support include insurance for clinical trials, assistance with identification and activation of research centres internationally, amongst others.